Use of Immunotherapeutic Expanded to Kidney Cancer
The FDA expanded the use of the immune checkpoint inhibitor nivolumab to include certain patients with kidney cancer.
Progress Against Cancer
The FDA expanded the use of the immune checkpoint inhibitor nivolumab to include certain patients with kidney cancer.
The FDA approved a new therapeutic, ixazomib, for treating certain patients with multiple myeloma. Learn about this FDA treatment approval.
The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic elotuzumab (Empliciti) for treating certain patients with multiple myeloma.
Daratumumab is intended for patients whose multiple myeloma has worsened despite receiving at least three other treatments for their disease.
The FDA approved a combination of molecularly targeted therapies for treating certain patients with melanoma.
A first-of-its kind immunotherapeutic has been approved by the FDA for the treatment of melanoma lesions in the skin and lymph nodes.
The FDA has approved trabectedin for the treatment of certain patients with two types of soft tissue sarcoma, liposarcoma and leiomyosarcoma.
A nanotherapeutic form of the conventional chemotherapeutic has been approved by the FDA for treating certain patients with pancreatic cancer.
The FDA has expanded the use of an immune checkpoint inhibitor for the treatment of patients with lung cancer.
The FDA has approved a targeted therapy for certain patients with lung cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More